APTO Stock Overview
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Aptose Biosciences Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$1.27 |
| 52 Week High | CA$8.70 |
| 52 Week Low | CA$1.20 |
| Beta | 1.42 |
| 1 Month Change | -15.33% |
| 3 Month Change | -41.74% |
| 1 Year Change | -82.36% |
| 3 Year Change | -98.32% |
| 5 Year Change | -95.77% |
| Change since IPO | -99.99% |
Recent News & Updates
Recent updates
Aptose Biosciences Q2 2022 Earnings Preview
Aug 01Aptose Biosciences Continues To Drift Without Thesis-Changing Data
Jul 19Aptose Deep In The Doghouse Due To Lack Of Pipeline Progress
Feb 02Aptose: High Risk, High Reward. Watch Its Phase I Studies
Aug 05Aptose Biosciences (APTO) Presents Corporate Update at EHA 2021 - Slideshow
Jun 18Aptose Biosciences: An Assessment
Apr 27Aptose Shares Sell Off As The Market Wanted More Than Further Signs And Portents
Dec 08Aptose Shares Look Undervalued Ahead Of Value-Driving Efficacy Data
Nov 12Shareholder Returns
| APTO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -8.0% | -4.7% | -3.7% |
| 1Y | -82.4% | -2.7% | 20.2% |
Return vs Industry: APTO underperformed the US Biotechs industry which returned -2% over the past year.
Return vs Market: APTO underperformed the US Market which returned 20.5% over the past year.
Price Volatility
| APTO volatility | |
|---|---|
| APTO Average Weekly Movement | 9.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: APTO's share price has been volatile over the past 3 months.
Volatility Over Time: APTO's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1986 | 36 | William Rice | www.aptose.com |
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. Its clinical programs include APTO-253, which is in Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS); and Tuspetinib, an oral potent myeloid kinase inhibitor that is in Phase 1/2 clinical trial to treat patients with relapsed or refractory AML. The company also develops luxeptinib, an orally administered, and potent dual lymphoid and myeloid kinome inhibitor that is in Phase 1a/b clinical trial for treating patients with relapsed or refractory B-cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and various non-Hodgkin’s lymphomas, as well as AML and HR MDS.
Aptose Biosciences Inc. Fundamentals Summary
| APTO fundamental statistics | |
|---|---|
| Market cap | US$19.98m |
| Earnings (TTM) | -US$51.21m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.4x
P/E RatioIs APTO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| APTO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$51.21m |
| Earnings | -US$51.21m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.26 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did APTO perform over the long term?
See historical performance and comparison